Casein glycomacropeptide (CGMP)

DIETARY_SUPPLEMENT2 trials

Sponsors

University of Aarhus, Oregon State University

Conditions

Colitis, UlcerativeInflammatory Bowel DiseasesInflammatory Bowel Syndrome

Unknown Phase

CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)

CompletedNCT02825914

University of AarhusColitis, Ulcerative, Inflammatory Bowel Diseases

Start: 2016-09-01End: 2019-10-01Updated: 2020-04-07

Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

CompletedNCT05482464

Oregon State UniversityInflammatory Bowel Syndrome

Start: 2022-01-01End: 2024-09-01Updated: 2025-04-04